First-line sunvozertinib in NSCLC with EGFR exon 20 insertion mutations (Registro nro. 22854)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03490nam a2200349 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260821122750.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Zhou, Caicun |
| Rol del Autor | Autor |
| 9 (RLIN) | 54258 |
| 245 ## - Titulo | |
| Titulo | First-line sunvozertinib in NSCLC with EGFR exon 20 insertion mutations |
| 300 ## - Páginas | |
| Paginación | páginas: 765-775 |
| 520 ## - Resumen | |
| Resumen | Background: Sunvozertinib received accelerated approval for use in later lines of therapy for patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Data are needed on the efficacy and safety of sunvozertinib as a first-line treatment for NSCLC. Methods: In this phase 3, international trial, we randomly assigned, in a 1:1 ratio, patients with advanced nonsquamous NSCLC with EGFR exon 20 insertions to receive sunvozertinib or chemotherapy (carboplatin–pemetrexed). The primary end point was progression-free survival as assessed by blinded independent central review. Crossover to the sunvozertinib group was allowed after disease progression was confirmed. Secondary end points included overall survival, investigator-assessed progression-free survival, objective response (complete or partial response), change in tumor size, and duration of response. Results: A total of 324 patients were randomly assigned to receive sunvozertinib (163 patients) or chemotherapy (161 patients). Treatment with sunvozertinib led to significantly longer median progression-free survival than chemotherapy (10.3 vs. 7.5 months; hazard ratio for disease progression or death, 0.65; 95% confidence interval, 0.50 to 0.85; P<0.001). At 12 months, progression-free survival was reported in 46.1% of the patients in the sunvozertinib group and in 26.7% of those in the chemotherapy group; the data for overall survival were immature (38.9% maturity). The percentage of patients with an objective response was 58.9% in the sunvozertinib group and 31.1% in the chemotherapy group; the median best percentage change in tumor size was −42.1% and −24.7% respectively, and the median duration of response was 11.2 and 7.1 months. Grade 3 or higher adverse events were reported in 75.5% of the patients in the sunvozertinib group and in 56.7% of those in the chemotherapy group. In the sunvozertinib group, the most common adverse events of grade 3 or higher included increased serum creatine kinase levels, diarrhea, and anemia. No deaths were attributed to adverse events considered by the investigators to be related to sunvozertinib. Conclusions: The efficacy of sunvozertinib was superior to that of chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CÁNCER DE PULMÓN |
| 9 (RLIN) | 53712 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | NEUMOLOGÍA |
| 9 (RLIN) | 25628 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CUIDADOS INTENSIVOS GENERAL |
| 9 (RLIN) | 54115 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | TRATAMIENTOS EN ONCOLOGÍA |
| 9 (RLIN) | 53734 |
| 700 ## - Autor Personal | |
| Autor Personal | Greillier, Laurent |
| 9 (RLIN) | 54259 |
| 700 ## - Autor Personal | |
| Autor Personal | Liu, Geoffrey |
| 9 (RLIN) | 54260 |
| 700 ## - Autor Personal | |
| Autor Personal | John, Thomas |
| 9 (RLIN) | 54261 |
| 700 ## - Autor Personal | |
| Autor Personal | Xing, Ligang |
| 9 (RLIN) | 54262 |
| 700 ## - Autor Personal | |
| Autor Personal | Kowalski, Dariusz |
| 9 (RLIN) | 54263 |
| 700 ## - Autor Personal | |
| Autor Personal | Memmott, Regan M. |
| 9 (RLIN) | 54264 |
| 700 ## - Autor Personal | |
| Autor Personal | Yazici, Ozan |
| 9 (RLIN) | 54265 |
| 700 ## - Autor Personal | |
| Autor Personal | Sun, Meili |
| 9 (RLIN) | 54266 |
| 700 ## - Autor Personal | |
| Autor Personal | Shu, Catherine A. |
| 9 (RLIN) | 54267 |
| 700 ## - Autor Personal | |
| Autor Personal | Pons-Tostivint, Elvire |
| 9 (RLIN) | 54268 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22650 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM12 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-08-21 |
| Catalogador | sqb |
No hay ítems disponibles.